Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bradmer Pharmaceuticals, a biopharmaceutical company engaged in the development and commercialization of cancer therapies, has received a new European patent that covers the use of its lead product for glioblastoma, 131-Iodine Neuradiab candidate that binds to tenascin for the treatment of lymphoma, including non-Hodgkin lymphoma, by intravenous administration.
Subscribe to our email newsletter
According to the company, the patent includes antibodies that bind to the epitope bound by Neuradiab and the use of numerous radioisotopes conjugated to Neuradiab.
Alan Ezrin, president and CEO of Bradmer, said: “The issuance of this patent strengthens our patent portfolio and demonstrates the potential value of Neuradiab in applications beyond glioblastoma multiforme. The localized application of Neuradiab offers direct and specific tumor-killing radiation to solid tumors in the brain in addition to the typical benefits provided by radiolabeled therapies through systemic application.
“While our primary market remains focused upon glioblastoma, product extensions exist for Neuradiab in other markets. The direct intravenous injection of therapeutic dosages of Neuradiab bodes well for the safety associated with direct local application in brain tumors in which the treatment is embedded in the residual ridge with negligible systemic exposure.”